Theraclone Sciences uses its I-STAR™ technology platform to rapidly screen and identify rare, therapeutically relevant human monoclonal antibodies from immunologically relevant donors. The company has discovery collaborations with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative. Theraclone has two proprietary antibody programs in clinical development targeting pandemic/seasonal influenza and human cytomegalovirus (HCMV). Proceeds from the recent financing will advance those clinical programs and support ongoing discovery projects using the I-STAR platform. Management cites progress in lead development programs and the Pfizer collaboration as indicators of R&D strength. The company is headquartered in Seattle. Theraclone Sciences develops novel therapeutic human monoclonal antibodies for infectious disease and cancer using its I-STAR™ discovery platform. The platform is designed to rapidly screen and identify rare, potent and therapeutically relevant human antibodies from immunologically relevant donors. Theraclone isolates candidates that can be scaled for industrial production and that the company says may offer safety and broad patient relevance. The company is privately held and has existing venture backers including ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Amgen Ventures and Alexandria Real Estate Equities. Recent milestones cited by management include a discovery collaboration with Pfizer and the anticipated near-term initiation of Theraclone’s first clinical trial. Proceeds from the latest financing will support ongoing discovery projects and advance clinical programs.

Total raised

$25M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2013